Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.56M Buy
106,094
+16,651
+19% +$881K 0.08% 321
2026
Q1
$4.94M Buy
89,443
+18,014
+25% +$976K 0.08% 333
2025
Q4
$3.5M Sell
71,429
-8,533
-11% -$398K 0.06% 419
2025
Q3
$3.45M Sell
79,962
-18,997
-19% -$742K 0.06% 428
2025
Q2
$3.8M Sell
98,959
-24,824
-20% -$949K 0.07% 392
2025
Q1
$4.8M Sell
123,783
-3,868
-3% -$142K 0.09% 289
2024
Q4
$4.32M Sell
127,651
-14,697
-10% -$529K 0.08% 327
2024
Q3
$5.82M Buy
142,348
+14,565
+11% +$596K 0.11% 243
2024
Q2
$4.92M Buy
127,783
+8,047
+7% +$338K 0.1% 264
2024
Q1
$5.13M Buy
119,736
+6,559
+6% +$270K 0.1% 261
2023
Q4
$4.19M Sell
113,177
-629
-0.6% -$22.6K 0.09% 293
2023
Q3
$4.13M Buy
113,806
+2,847
+3% +$101K 0.09% 287
2023
Q2
$3.95M Sell
110,959
-1,845
-2% -$66.2K 0.08% 315
2023
Q1
$4.01M Sell
112,804
-3,148
-3% -$110K 0.08% 308
2022
Q4
$4.07M Buy
115,952
+11,385
+11% +$379K 0.08% 284
2022
Q3
$3.08M Sell
104,567
-301
-0.3% -$11.4K 0.06% 349
2022
Q2
$5.71M Buy
104,868
+9,946
+10% +$549K 0.11% 206
2022
Q1
$5.17M Buy
94,922
+14,647
+18% +$796K 0.08% 265
2021
Q4
$4.42M Buy
80,275
+8,189
+11% +$426K 0.06% 338
2021
Q3
$3.44M Buy
72,086
+7,616
+12% +$383K 0.05% 397
2021
Q2
$3.21M Sell
64,470
-4,570
-7% -$220K 0.05% 425
2021
Q1
$3.08M Sell
69,040
-2,367
-3% -$107K 0.05% 422
2020
Q4
$3.29M Sell
71,407
-9,567
-12% -$439K 0.05% 360
2020
Q3
$3.81M Sell
80,974
-4,652
-5% -$233K 0.07% 267
2020
Q2
$4.37M Sell
85,626
-14,138
-14% -$725K 0.09% 234
2020
Q1
$4.73M Sell
99,764
-4,279
-4% -$228K 0.11% 177
2019
Q4
$6.11M Sell
104,043
-6,200
-6% -$345K 0.11% 223
2019
Q3
$5.88M Sell
110,243
-9,729
-8% -$500K 0.11% 228
2019
Q2
$6M Sell
119,972
-12,804
-10% -$642K 0.11% 222
2019
Q1
$6.94M Sell
132,776
-2,460
-2% -$123K 0.13% 192
2018
Q4
$6.46M Sell
135,236
-10,438
-7% -$514K 0.13% 186
2018
Q3
$7.32M Sell
145,674
-1,102
-0.8% -$56K 0.12% 211
2018
Q2
$7.4M Buy
146,776
+5,343
+4% +$269K 0.13% 205
2018
Q1
$6.42M Buy
141,433
+3,992
+3% +$186K 0.11% 239
2017
Q4
$6.09M Buy
137,441
+287
+0.2% +$13.3K 0.1% 261
2017
Q3
$6.96M Buy
137,154
+10,758
+9% +$546K 0.12% 234
2017
Q2
$6.81M Buy
126,396
+12,706
+11% +$677K 0.11% 250
2017
Q1
$5.99M Sell
113,690
-25,605
-18% -$1.3M 0.1% 276
2016
Q4
$6.71M Sell
139,295
-5,083
-4% -$251K 0.11% 266
2016
Q3
$7.78M Sell
144,378
-17,926
-11% -$983K 0.13% 237
2016
Q2
$8.79M Sell
162,304
-9,526
-6% -$502K 0.14% 214
2016
Q1
$8.71M Sell
171,830
-29,188
-15% -$1.45M 0.14% 202
2015
Q4
$10.1M Sell
201,018
-7,754
-4% -$395K 0.16% 177
2015
Q3
$10M Sell
208,772
-15,607
-7% -$812K 0.16% 170
2015
Q2
$11.7M Buy
224,379
+8,348
+4% +$470K 0.16% 171
2015
Q1
$12.5M Buy
216,031
+3,630
+2% +$208K 0.17% 165
2014
Q4
$11.3M Sell
212,401
-3,857
-2% -$216K 0.15% 180
2014
Q3
$12.4M Buy
216,258
+10,342
+5% +$634K 0.17% 165
2014
Q2
$13.8M Buy
205,916
+26,659
+15% +$1.8M 0.19% 144
2014
Q1
$12M Buy
179,257
+15,466
+9% +$1.05M 0.18% 151
2013
Q4
$10.9M Buy
163,791
+22,022
+16% +$1.43M 0.18% 160
2013
Q3
$8.89M Buy
141,769
+13,938
+11% +$897K 0.16% 187
2013
Q2
$7.99M Buy
+127,831
New +$8.11M 0.15% 201

Other funds holding GSK

Advisors Asset Management's GSK Position: Q2 2026 in Review

Advisors Asset Management increased its GSK (GSK) stake by 19% in Q2 2026, buying an estimated $881K and bringing the position to 106,094 shares worth $5.56M. The position accounts for 0.08% of the portfolio, ranked #321.

Advisors Asset Management first reported a position in GSK in Q2 2013 and has held it in 53 quarters since. The position peaked at $13.8M in Q2 2014. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Advisors Asset Management held 106,094 shares of GSK worth $5.56M as of Q2 2026.
  • Advisors Asset Management bought 16,651 GSK shares in Q2 2026, an estimated $881K.
  • GSK made up 0.08% of Advisors Asset Management's portfolio in Q2 2026, its #321 holding.
  • Advisors Asset Management first reported a position in GSK in Q2 2013 and has held it in 53 quarters since.
  • Advisors Asset Management's GSK position peaked at $13.8M in Q2 2014.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.